Otsuka’s release of supplemental Phase III data on June 6 for sibeprenlimab was the second major data readout in immunoglobulin A nephropathy (IgAN) of the week, following Vera’s Phase III data on June 2, and both look like approvable drug candidates that can take on the four currently approved IgAN (aka Berger’s disease) therapies.
Key Takeaways
- Otsuka is hoping to join the crowded IgAN therapy market with a selective APRIL inhibitor now under FDA review with a November action date.
The Japanese pharma’s selective APRIL (A PRliferation-Inducing Ligand) inhibitor sibeprenlimab demonstrated statistically significant and clinically meaningful reduction of proteinuria –...
